


Supplemental Figure S1.



Supplementary Figure S1. Over 48 hours, cEND cells were exposed to pooled ACVD and MMD patient serum and compared with cells kept in 2% FCS (normal conditions) and TER **(A)** and the extracellular production of proMMP-9 **(B)**, VEGF **(C)** and Ang-2 **(D)** was tested by ELISA assays. Values in the graphs are means \pm SEM, (n=3 independent experiments performed in triplicates each including at least 5 different pooled patients' serum of each clinical type), ****/#### $P < 0.001$, ***/### $P < 0.005$ versus FCS-incubated cENDs, One-Way ANOVA. Relative gene expression of MMP-9, VEGF and Ang-2 **(E)**, as well as claudin-5, occludin and VE-cadherin **(F)** depicted as fold of ACVD-incubated cEND cells was tested after a 24-hour exposure to patients' serum and FCS. Values in the graphs are means \pm SEM, (n=3 independent experiments performed in triplicates each including at least 5 different pooled patients' serum of each clinical type) **** $P < 0.001$, ** $P < 0.01$ versus ACVD-incubated cENDs, One-Way ANOVA.

Abbreviations: ACVD = atherosclerotic cerebrovascular disease; Ang-2 = angiotensin-2; ELISA = enzyme-linked immunosorbent assay; FCS = fetal calf serum; MMD = Moyamoya

disease; MMP-9 = matrix metalloproteinase-9; TER = transendothelial electrical resistance;
VE-cadherin = vascular-endothelial cadherin; VEGF = vascular-aneothelial growth factor;